Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease

Neurology

Volumn 51, Issue 1, 1998, Pages 203-206

  Verhagen Metman, L ^a   Del Dotto, P ^a,b   Natte R ^a   Van Den Munckhof, P ^a   Chase, Thomas N ^a,c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b National Parkinson Foundation   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTROMETHORPHAN; LEVODOPA;

ADULT; AGED; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; HUMAN; NEUROTRANSMISSION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0345084477     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.1.203     Document Type: Article

References (30)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth, 1981: 96-122.
2. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesia in Parkinson's disease. Ann Neurol 1989;25:523-526.
3. Verhagen Metman L, van den Munckhof P, Klaassen AAG, Blanchet P, Mouradian MM, Chase TN. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology 1997;49:711-713.
4. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
5. Verhagen Metman L, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48: 369-372.
6. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996;69:497-501.
7. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-2588.
8. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995; 701:13-18.
9. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
10. Wong BY, Coulter DA, Choi DW, Prince DA. Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices. Neurosci Lett 1988;85:261-266.
11. Church J, Jones MG, Davies SN, Lodge D. Antitussive agents as N-methylaspartate antagonists: further studies. Can J Physiol Pharmacol 1989;67:561-567.
12. Albers GW, Saenz RE, Moses JA Jr. Tolerability of oral dextromethorphan in patients with a history of brain ischemia. Clin Neuropharmacol 1992;15:509-514.
13. Walker FO, Hunt UP. An open label trial of dextromethorphan in Huntington's disease. Clin Neuropharmacol 1989;12: 322-330.
14. Hollander D, Pradas J, Kaplan R, McLeod HL, Evans WE, Munsat TL. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. Ann Neurol 1994;36:920-924.
15. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997;48: 1212-1218.
16. Bonuccelli U, Del Dotto P, Piccini P, Beghé F, Corsini GU, Muratorio A. Dextromethorphan and parkinsonism. Lancet 1992;340:53. Letter.
17. Montastruc JL, Fabre N, Rascol O, Senard JM, Blin O. N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan. Mov Disord 1994;9:242-243.
18. Verhagen Metman L, Blanchet PJ, Mouradian MM, Chase TN. Dextromethorphan and levodopa combination therapy in parkinsonian patients with response fluctuations. Mov Disord 1996;11:184. Abstract.
19. Woodworth JR, Dennis SRK, Moore L, Rotenberg KS. The polymorphic metabolism of dextromethorphan. J Clin Pharmacol 1987;27:139-143.
20. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992;51:647-655.
21. Schadel M, Wu D, Otton SV, Kalow W, Sellers EM. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 1995;15:263-269.
22. Davis TL, Brughitta G, Baronti F, Mouradian MM. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991;41:630-633.
23. Blanchet PJ, Verhagen Metman L, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 1996;11:580-581.
24. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
25. Debonnel G, De Montigny C. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 1996;58:721-734.
26. Brent PJ. Behavioural effect of pretreatment with opioid antagonists and sigma binding site ligands on the abnormal motor response produced by the kappa opioid agonist U50,488H in guinea pigs. Neuropharmacology 1993;32:751-760.
27. Maneuf YP, Mitchell IJ, Crossman AR, Woodruff GN, Brotchie JM. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res 1995;683:102-108.
28. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997;42:720-726.
29. Kieburtz K, Feigin A, McDermott M, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996;11:273-277.
30. Rupniak NMJ, Boyce S, Steventon MJ, Iversen SD, Marsden CD. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys. Ann Neurol 1992;32: 103-105.